By InvitationNot Applicable

Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases

Russia400 participantsStarted 2023-01-30

Plain-language summary

Assessment of cardiovascular disorders using echocardiography and arterial stiffness; comparative noninvasive assessment of volatile organic compound (eVOC) exhale breath patterns in patients with different chronic respiratory diseases with age and gender-matched healthy adults in order to identify a disease-specific exhaled eVOCs profiles and markers of respiratory and cardiovascular disorders.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent to participate in the study;
✓. Age 18 and over;
✓. Clinical diagnosis of one of chronic respiratory diseases (COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis or other interstitial lung disease).

Exclusion criteria

✕. Unable to sign informed consent;
✕. Respiratory disease (for controls);
✕. Mental illness (severe dementia, schizophrenia, severe depression, manic-depressive psychosis);
✕. Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism within the last 3 months;
✕. Oncology;
✕. Previous lung transplantation (for patients with respiratory diseases);
✕. Diseases and conditions that can change the ECG picture and complicate the analysis of the ECG (conduction disturbance, pacemaker);
✕. Inability to use a heart monitor (congenital developmental anomalies, traumatic amputation of the upper limbs, essential tremor, Parkinson's disease);

What they're measuring

Molecular composition of exhaled breath analysed by proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria)

Timeframe: up to 3 years

Results of recording an electrocardiogram (ECG) in one lead with an assessment of the pulse wave

Timeframe: up to 3 years

Indicators of arterial stiffness

Timeframe: up to 3 years

Trial details

NCT IDNCT05727852

SponsorI.M. Sechenov First Moscow State Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01

View on ClinicalTrials.gov More Chronic Respiratory Diseases trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent to participate in the study;
✓. Age 18 and over;
✓. Clinical diagnosis of one of chronic respiratory diseases (COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis or other interstitial lung disease).

Exclusion criteria

✕. Unable to sign informed consent;
✕. Respiratory disease (for controls);
✕. Mental illness (severe dementia, schizophrenia, severe depression, manic-depressive psychosis);
✕. Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism within the last 3 months;
✕. Oncology;
✕. Previous lung transplantation (for patients with respiratory diseases);
✕. Diseases and conditions that can change the ECG picture and complicate the analysis of the ECG (conduction disturbance, pacemaker);
✕. Inability to use a heart monitor (congenital developmental anomalies, traumatic amputation of the upper limbs, essential tremor, Parkinson's disease);

What they're measuring

Molecular composition of exhaled breath analysed by proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria)

Timeframe: up to 3 years

Results of recording an electrocardiogram (ECG) in one lead with an assessment of the pulse wave

Timeframe: up to 3 years

Indicators of arterial stiffness

Timeframe: up to 3 years